Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients

Hepatology

Volumn 61, Issue 3, 2015, Pages 790-801

  Meissner, Eric G ^a   Lee, Yu Jin ^a   Osinusi, Anu ^a,b   Sims, Zayani ^c   Qin, Jing ^a   Sturdevant, Dan ^d   Mchutchison, John ^e   Subramanian, Mani ^e   Sampson, Maureen ^f   Naggie, Susanna ^g   Patel, Keyur ^g   Remaley, Alan T ^f   Masur, Henry ^c   Kottilil, Shyam ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e GILEAD SCIENCES   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LEDIPASVIR; LIPID; LOW DENSITY LIPOPROTEIN; RIBAVIRIN; SOFOSBUVIR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EVENING DOSAGE; FATTY ACID METABOLISM; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORNING DOSAGE; PARTICLE SIZE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; VIROLOGY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIPID METABOLISM; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RIBAVIRIN; SOFOSBUVIR; URIDINE MONOPHOSPHATE; VIRUS REPLICATION;

EID: 84923313380     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27424     Document Type: Article

References (48)

1. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins-impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013;5:1292-1324.
2. Negro F. Hepatitis C in 2013: HCV causes systemic disorders that can be cured. Nat Rev Gastroenterol Hepatol 2014;11:77-78.
3. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-115.
4. Negro F. HCV infection and metabolic syndrome: which is the chicken and which is the egg? Gastroenterology 2012;142:1288-1292.
5. Sheridan DA, Neely RD, Bassendine MF. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clin Res Hepatol Gastroenterol 2013;37:10-16.
6. Petta S, Rosso C, Leung R, Abate ML, Booth D, Salomone F, et al. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11:311-317 e311.
7. Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006;130:1661-1669.
8. Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010;52:864-874.
9. Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, et al. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J Gastroenterol Hepatol 2013;28:51-56.
10. Rao GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology 2011;140:144-152.
11. Cheng FK, Torres DM, Harrison SA. Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? J Viral Hepat 2014;21:1-8.
12. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013;11:482-496.
13. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089-1097.
14. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr., Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 2007;104:5848-5853.
15. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006;80:2418-2428.
16. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, Andre P, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 2011;286:3018-3032.
17. Li Q, Pene V, Krishnamurthy S, Cha H, Liang TJ. Hepatitis C virus infection activates an innate pathway involving IKK-alpha in lipogenesis and viral assembly. Nat Med 2013;19:722-729.
18. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-1131.
19. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007;81:8122-8130.
20. Fujino T, Nakamuta M, Yada R, Aoyagi Y, Yasutake K, Kohjima M, et al. Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver. Hepatol Res 2010;40:923-929.
21. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002;99:15669-15674.
22. Bose SK, Kim H, Meyer K, Wolins N, Davidson NO, Ray R. Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus. J Virol 2014;88:4195-4203.
23. Serfaty L, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut 2012;61:1473-1480.
24. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310:804-811.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
26. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-870.
27. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014;124:3352-3363.
28. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009;30:710-717.
29. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997;157:792-796.
30. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013;5:928-948.
31. Milner KL, Jenkins AB, Trenell M, Tid-Ang J, Samocha-Bonet D, Weltman M, et al. Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. J Viral Hepat 2014;21:325-332.
32. Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011;55:1187-1194.
33. Syed GH, Tang H, Khan M, Hassanein T, Liu J, Siddiqui A. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol 2014;88:2519-2529.
34. Rojas A, del Campo JA, Maraver M, Aparcero R, Garcia-Valdecasas M, Diago M, et al. Hepatitis C virus infection alters lipid metabolism depending on IL28B polymorphism and viral genotype and modulates gene expression in vivo and in vitro. J Viral Hepat 2014;21:19-24.
35. Yu C, Boon D, McDonald SL, Myers TG, Tomioka K, Nguyen H, et al. Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J Virol 2010;84:11264-11278.
36. Chang ML, Yeh CT, Chen JC, Huang CC, Lin SM, Sheen IS, et al. Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics 2008;9:109.
37. Nakamuta M, Yada R, Fujino T, Yada M, Higuchi N, Tanaka M, et al. Changes in the expression of cholesterol metabolism-associated genes in HCV-infected liver: a novel target for therapy? Int J Mol Med 2009;24:825-828.
38. Lefebvre P, Staels B. Failing FXR expression in the liver links aging to hepatic steatosis. J Hepatol 2014;60:689-690.
39. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 2014;59:2403-2412.
40. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009;50:1030-1037.
41. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 2014;40:315-327.
42. Fullerton JN, O'Brien AJ, Gilroy DW. Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol 2014;35:12-21.
43. Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011;55:1195-1200.
44. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, et al. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014;209:1700-1704.
45. Sun HY, Lin CC, Lee JC, Wang SW, Cheng PN, Wu IC, et al. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Gut 2013;62:1193-1203.
46. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005;102:2561-2566.
47. Rowell J, Thompson AJ, Guyton JR, Lao XQ, McHutchison JG, McCarthy JJ, Patel K. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol Int 2012;6:475-481.
48. Osinusi, A, Kohli, A, Marti, MM, Nelson, A, Zhang, X, Meissner, EG, Silk, R, Townsend, K, et al. Retreatment of HCV genotype-1 with sofosbuvir and ledipasvir after relapse with sofosbuvir and ribavirin: a pilot study. Ann Intern Med 2014;161 (in press).